Year-End Report 19/20
September 2019 – August 2020, Diamyd Medical AB (publ), Fiscal year 2019/2020Significant effect of Diamyd® demonstrated in a large predefined patient group, covering about 40-50 percent of all type 1 diabetes patientsDiamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.Further information is available on https://www.diamyd.com Figures in parentheses relate to the corresponding period previous financial year. September 1, 2019 – August 31, 2020 · Net result: MSEK 9.7 (-36.6), whereof fourth quarter MSEK -13.5 (-9.8). The increase